Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.46 |
| ▸ | HTR3B | O95264 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11772520 | 0.85 | CYP2D6 (0.50) | SMN1; SMN2MAPTNPC1HPGDRAB9A | |
| Hydrochloric Acid SCHEMBL11772515 | 0.85 | CYP2D6 (0.50) | SMN1; SMN2MAPTNPC1HPGDRAB9A | |
| SCHEMBL16469275 | 0.81 | NOS3 (0.53) | SMN1; SMN2MAPTNPC1HPGDRAB9A | |
| SCHEMBL21379771 | 0.77 | HTR3E (0.52) | SMN1; SMN2NPC1HPGDRAB9AHTR3E | |
| SCHEMBL21379768 | 0.77 | HTR3E (0.52) | SMN1; SMN2NPC1HPGDRAB9AHTR3E | |
| Hydrochloric Acid SCHEMBL11770327 | 0.76 | TAAR1 (0.65) | SMN1; SMN2MAPTNPC1HPGDRAB9A | |
| Hydrochloric Acid SCHEMBL11772727 | 0.75 | HTR3E (0.53) | SMN1; SMN2NPC1HPGDRAB9AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL11772735 | 0.75 | HTR3E (0.53) | SMN1; SMN2NPC1HPGDRAB9AL3MBTL1 | |
| SCHEMBL23879961 | 0.74 | GAA (0.61) | SMN1; SMN2MAPTNPC1HPGDRAB9A | |
| SCHEMBL105256 | 0.74 | GAA (0.61) | SMN1; SMN2MAPTNPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653673-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-20180161312-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | US | disclosed |
| US-9974775-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-22 | — | — | US | disclosed |
| EP-3033337-B1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-28 | — | — | EP | disclosed |
| US-20160310468-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-27 | — | — | US | disclosed |
| US-9453002-B2 | Substituted imidazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| EP-3033337-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | Janssen Pharmaceutica, N.V. (BE) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015023289-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | WO | disclosed |
| US-20150051225-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051225-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1S | SMN1; SMN2 603/4885MAPT 1070/4885NPC1 643/4885 |
| US-10653673-B2 | Substituted imidazoles as N-type calcium channel blockers | CACNA1B, CACNA1E, CACNA1S | SMN1; SMN2 603/4885MAPT 1070/4885NPC1 643/4885 |
| US-20180161312-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1S | SMN1; SMN2 603/4885MAPT 1070/4885NPC1 643/4885 |
| US-20160310468-A1 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1S | SMN1; SMN2 603/4885MAPT 1070/4885NPC1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.